Verdiperstat in Amyotrophic Lateral Sclerosis

Overview of attention for article published in JAMA Neurology, February 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 10 news outlets
blogs: 2 blogs
twitter: 16 X users
facebook: 3 Facebook pages

video: 1 YouTube creator
bluesky: 1 Bluesky user
podcasts: 1 podcast

Readers on

mendeley: 32 Mendeley

So far, Altmetric has seen 13 news stories from 10 outlets.

Verdiperstat no puede mejorar la progresión de la enfermedad de la ELA, los resultados de Healey-Als muestran

Espanol.news, 16 May 2025

Mérito E. Cudkowicz, MD, MSC Resultados oficiales del brazo Verdiperstat (Biohaven) de la prueba de plataforma Healey-Al (NCT0429…

Verdiperstat Fails to Improve ALS Disease Progression, HEALEY-ALS Results Show

Neurology Live, 15 May 2025

Verdiperstat failed to significantly slow ALS progression or improve survival in the HEALEY-ALS Platform trial.

Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

Alzforum, 21 Mar 2025

Writing Committee for the HEALEY ALS Platform Trial, Shefner JM, Oskarsson B, Macklin EA, Chibnik LB, Quintana M, Saville BR…

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

Alzforum, 21 Mar 2025

Writing Committee for the HEALEY ALS Platform Trial, Berry JD, Maragakis NJ, Macklin EA, Chibnik LB, Quintana M, Saville BR…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 9 additional news stories.